Followers | 16 |
Posts | 1145 |
Boards Moderated | 0 |
Alias Born | 03/12/2010 |
Thursday, April 25, 2013 1:38:07 PM
April 18, 2013
Biotech company Pharming Group NV announces the analyst report completed by Joseph Pantginis, Ph.D. and Raluca Pancrotov, Ph.D. from Roth Capital Partners is published today.
Pharming and Santarus (SNTS - Buy) announced the filing of a BLA with the FDA for Ruconest as treatment for acute hereditary angioedema (HAE), as anticipated. We view this announcement as positive for Pharming; upon the FDA accepting the BLA filing, the company is eligible for a $5 million milestone payment from SNTS. A $20 million milestone payment is also expected upon first commercial U.S. sale. We reiterate our Buy rating.
https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=2212829b-a2f3-4802-b856-8a7b1293ab54&mime=pdf&co=Roth2&id=morningcallmin@roth.com&source=mail&pdfFileExtension=.pdf
Recent PHARM News
- Pharming Group to report first quarter 2024 financial results on May 8 • GlobeNewswire Inc. • 04/24/2024 06:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/19/2024 04:43:36 PM
- Pharming Group announces the placement of €100 million convertible bonds due 2029 • GlobeNewswire Inc. • 04/18/2024 01:04:30 PM
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/18/2024 06:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming Group announces the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/04/2024 06:30:00 AM
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F • GlobeNewswire Inc. • 04/04/2024 05:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
- Pharming Group reports fourth quarter and full year 2023 financial results • GlobeNewswire Inc. • 03/14/2024 06:00:00 AM
- Pharming Group to report fourth quarter and full year 2023 financial results on March 14 • GlobeNewswire Inc. • 02/29/2024 07:00:00 AM
- Pharming Group to report fourth quarter and full year 2023 financial results on March 14 • GlobeNewswire Inc. • 02/29/2024 07:00:00 AM
- Pharming Group to participate in February investor conferences • GlobeNewswire Inc. • 02/08/2024 07:00:00 AM
- Pharming Group to participate in February investor conferences • GlobeNewswire Inc. • 02/08/2024 07:00:00 AM
- Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update • GlobeNewswire Inc. • 01/08/2024 06:00:00 AM
- Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update • GlobeNewswire Inc. • 01/08/2024 06:00:00 AM
- Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) • GlobeNewswire Inc. • 12/13/2023 06:00:00 AM
- Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib • GlobeNewswire Inc. • 11/21/2023 06:00:00 AM
- Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib • GlobeNewswire Inc. • 11/21/2023 06:00:00 AM
- Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval • GlobeNewswire Inc. • 11/10/2023 01:51:10 PM
- Pharming Group to participate in November investor conferences • GlobeNewswire Inc. • 11/01/2023 07:00:00 AM
- Pharming Group to participate in November investor conferences • GlobeNewswire Inc. • 11/01/2023 07:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM